Diseases [C] » Pathological Conditions, Signs and Symptoms [C23] » Pathologic Processes
Description
The abnormal mechanisms and forms involved in the dysfunctions of tissues and organs. MeSH
Hierarchy View
Subtype Terms (65)
Arrhythmias, Cardiac
108 drugs (74 approved, 34 experimental)
Ascites
66 drugs (37 approved, 29 experimental)
Atrial Remodeling
3 approved drugs
Cardiotoxicity
62 drugs (53 approved, 9 experimental)
Chromosome Aberrations
32 drugs (26 approved, 6 experimental)
Death
21 drugs (12 approved, 9 experimental)
Dehydration
16 drugs (7 approved, 9 experimental)
Delayed Graft Function
21 drugs (14 approved, 7 experimental)
Disease
6 drugs (3 approved, 3 experimental)
Disease Attributes
1 experimental drug
Dysbiosis
23 drugs (9 approved, 14 experimental)
Emphysema
40 drugs (31 approved, 9 experimental)
Extravasation of Diagnostic and Therapeutic Materials
4 drugs (2 approved, 2 experimental)
Femoracetabular Impingement
10 drugs (6 approved, 4 experimental)
Fibrosis
193 drugs (134 approved, 59 experimental)
Frailty
30 drugs (15 approved, 15 experimental)
Granuloma
38 drugs (29 approved, 9 experimental)
Granulomatosis, Orofacial
1 approved drug
Growth Disorders
32 drugs (15 approved, 17 experimental)
Hemolysis
13 drugs (10 approved, 3 experimental)
Hemorrhage
161 drugs (112 approved, 49 experimental)
Hyperammonemia
3 approved drugs
Hyperbilirubinemia
10 drugs (3 approved, 7 experimental)
Hyperplasia
25 drugs (17 approved, 8 experimental)
Hyperuricemia
57 drugs (19 approved, 38 experimental)
Hypovolemia
17 drugs (6 approved, 11 experimental)
Inflammation
495 drugs (230 approved, 265 experimental)
Intraoperative Complications
13 drugs (12 approved, 1 experimental)
Ischemia
64 drugs (35 approved, 29 experimental)
Leukocytosis
1 experimental drug
Long Term Adverse Effects
2 drugs (1 approved, 1 experimental)
Menstruation Disturbances
30 drugs (21 approved, 9 experimental)
Metaplasia
2 approved drugs
Muscle Weakness
47 drugs (27 approved, 20 experimental)
Necrosis
6 drugs (4 approved, 2 experimental)
Neointima
2 approved drugs
Neoplastic Processes
2 drugs (1 approved, 1 experimental)
Nerve Degeneration
18 drugs (12 approved, 6 experimental)
Ossification, Heterotopic
6 drugs (4 approved, 2 experimental)
Ototoxicity
14 drugs (10 approved, 4 experimental)
Pigmentation Disorders
6 approved drugs
Postoperative Complications
209 drugs (152 approved, 57 experimental)
Protein Aggregation, Pathological
Respiratory Aspiration
27 drugs (25 approved, 2 experimental)
Sclerosis
71 drugs (48 approved, 23 experimental)
Shock
48 drugs (35 approved, 13 experimental)
Toxic Optic Neuropathy
1 experimental drug
Ulcer
74 drugs (43 approved, 31 experimental)
Vascular Remodeling
1 approved drug
Yang Deficiency
2 approved drugs
Yin Deficiency
2 approved drugs
Phase 4 Indicated Drugs (4)
Phase 1 Indicated Drugs (4)
Other Experimental Indicated Drugs (7)
Organization Involved with Phase 4 Indications (10)
Organization Involved with Phase 3 Indications (3)
Organization Involved with Phase 2 Indications (23)
Organization Involved with Phase 1 Indications (9)
Organization Involved with Other Experimental Indications (2)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
